National Footprint of NEXICART-2 Trial Sites Expanded On track for first Biologics License Application (BLA) approved cell therapy in unaddressed orphan indication NEXICART-2 interim results were presented at ASCO 2025 LOS ANGELES, CA, July 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”... Read More